ZA201900507B - Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof - Google Patents

Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof

Info

Publication number
ZA201900507B
ZA201900507B ZA2019/00507A ZA201900507A ZA201900507B ZA 201900507 B ZA201900507 B ZA 201900507B ZA 2019/00507 A ZA2019/00507 A ZA 2019/00507A ZA 201900507 A ZA201900507 A ZA 201900507A ZA 201900507 B ZA201900507 B ZA 201900507B
Authority
ZA
South Africa
Prior art keywords
sfgfr3
polypeptides
growth factor
factor receptor
fibroblast growth
Prior art date
Application number
ZA2019/00507A
Other languages
English (en)
Inventor
Gouze Elvire
Garcia Stéphanie
Original Assignee
Therachon Sas
Inst Nat Sante Rech Med
Univ Nice Sophia Antipolis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therachon Sas, Inst Nat Sante Rech Med, Univ Nice Sophia Antipolis filed Critical Therachon Sas
Publication of ZA201900507B publication Critical patent/ZA201900507B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA2019/00507A 2016-07-07 2019-01-24 Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof ZA201900507B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662359607P 2016-07-07 2016-07-07
US201762467478P 2017-03-06 2017-03-06
PCT/EP2017/067119 WO2018007597A1 (en) 2016-07-07 2017-07-07 Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
ZA201900507B true ZA201900507B (en) 2023-04-26

Family

ID=59381265

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/00507A ZA201900507B (en) 2016-07-07 2019-01-24 Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof

Country Status (20)

Country Link
US (3) US10294289B2 (https=)
EP (2) EP3481859B1 (https=)
JP (2) JP7046903B2 (https=)
KR (2) KR20220122762A (https=)
CN (1) CN109715658B (https=)
AU (2) AU2017294551B2 (https=)
BR (1) BR112019000257A2 (https=)
CA (1) CA3029877C (https=)
DK (1) DK3481859T3 (https=)
ES (1) ES2912559T3 (https=)
HU (1) HUE058734T2 (https=)
IL (1) IL264030A (https=)
MX (1) MX2018016257A (https=)
PL (1) PL3481859T3 (https=)
PT (1) PT3481859T (https=)
RU (1) RU2751483C2 (https=)
SG (1) SG11201900074WA (https=)
SI (1) SI3481859T1 (https=)
WO (1) WO2018007597A1 (https=)
ZA (1) ZA201900507B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
MX2018016257A (es) 2016-07-07 2019-11-21 Therachon Sas Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
JP7335247B2 (ja) * 2017-09-20 2023-08-29 ファイザー・インク 可溶性線維芽細胞増殖因子受容体３（ｓＦＧＦＲ３）ポリペプチドを使用した異常内臓脂肪蓄積の処置
WO2020243478A1 (en) * 2019-05-29 2020-12-03 Massachusetts Eye And Ear Infirmary Fibroblast growth factor 2 (fgf2) for treatment of human sensorineural hearing loss
US11625937B2 (en) * 2020-04-06 2023-04-11 Toyota Motor Engineering & Manufacturing North America, Inc. Methods and systems for monitoring human body weight with vehicle sensors and big data AI analytics
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
WO2022254319A1 (en) 2021-06-01 2022-12-08 Pfizer Inc. Cell culture method for producing sfgfr3 polypeptide
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
CN116284327A (zh) * 2023-03-28 2023-06-23 中国药科大学 一种靶向肿瘤的成纤维细胞生长因子19的重组蛋白及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
WO1996041620A1 (en) 1995-06-12 1996-12-27 Yeda Research And Development Co., Ltd. Fgfr3 as a marker for mesenchymal skeletal progenitor cells
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
AU2002235202A1 (en) 2000-12-18 2002-07-01 Gene Logic, Inc. Treatment of bone disorders by modulation of fgfr3
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
JP2003104908A (ja) 2001-09-28 2003-04-09 Ichikazu Nakao 軟骨無形成症治療剤
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
ES2374822T3 (es) 2004-02-24 2012-02-22 Allergan, Inc. Ensayo de selección de toxinas botul�?nicas.
EP2083081A1 (en) 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
EP2083846B1 (en) 2006-09-28 2015-07-15 Hepacore Ltd. N-terminal fgf variants having increased receptor selectivity and uses thereof
WO2008133873A2 (en) 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
EP2318529B1 (en) * 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
MA33208B1 (fr) 2009-03-25 2012-04-02 Genentech Inc Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
US8445445B2 (en) 2009-09-15 2013-05-21 Five Prime Therapeutics, Inc. Method of promoting hair growth using FGFR4 extracellular domains
LT2498799T (lt) 2009-11-13 2016-11-10 Five Prime Therapeutics, Inc. Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
RU2012134637A (ru) 2010-01-14 2014-02-20 Йейл Юниверсити Ингибиторы рецепторных тирозинкиназ (rtk) и способы их применения
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
WO2012088608A1 (en) 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof
CN102219860B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
JP6162707B2 (ja) 2011-10-24 2017-07-12 ハロザイム インコーポレイテッド 抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
WO2014018673A2 (en) 2012-07-24 2014-01-30 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US20140030259A1 (en) 2012-07-27 2014-01-30 Genentech, Inc. Methods of treating fgfr3 related conditions
US11230589B2 (en) 2012-11-05 2022-01-25 Foundation Medicine, Inc. Fusion molecules and uses thereof
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
PE20170256A1 (es) 2014-01-24 2017-04-22 Ngm Biopharmaceuticals Inc Proteinas de union y sus metodos de uso
EP3242888B8 (en) 2015-01-07 2021-06-02 Pfizer Inc. Soluble fgfr3 decoys for treating skeletal growth disorders
MX2018016257A (es) 2016-07-07 2019-11-21 Therachon Sas Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
JP7335247B2 (ja) 2017-09-20 2023-08-29 ファイザー・インク 可溶性線維芽細胞増殖因子受容体３（ｓＦＧＦＲ３）ポリペプチドを使用した異常内臓脂肪蓄積の処置

Also Published As

Publication number Publication date
CN109715658A (zh) 2019-05-03
US20210309718A1 (en) 2021-10-07
KR20220122762A (ko) 2022-09-02
RU2019100381A (ru) 2020-08-11
SI3481859T1 (sl) 2022-07-29
HUE058734T2 (hu) 2022-09-28
EP4122955A1 (en) 2023-01-25
US11697678B2 (en) 2023-07-11
CN109715658B (zh) 2023-09-12
JP2019527053A (ja) 2019-09-26
AU2017294551B2 (en) 2022-03-03
MX2018016257A (es) 2019-11-21
ES2912559T3 (es) 2022-05-26
EP3481859A1 (en) 2019-05-15
RU2751483C2 (ru) 2021-07-14
AU2022202906A1 (en) 2022-05-26
PT3481859T (pt) 2022-05-23
WO2018007597A1 (en) 2018-01-11
CA3029877A1 (en) 2018-01-11
AU2017294551A1 (en) 2019-01-31
DK3481859T3 (da) 2022-04-25
RU2019100381A3 (https=) 2020-11-23
US20180230197A1 (en) 2018-08-16
JP7046903B2 (ja) 2022-04-04
SG11201900074WA (en) 2019-02-27
KR20190037240A (ko) 2019-04-05
BR112019000257A2 (pt) 2019-10-01
KR102432192B1 (ko) 2022-08-12
CA3029877C (en) 2023-07-25
JP7348980B2 (ja) 2023-09-21
US20200190162A1 (en) 2020-06-18
EP3481859B1 (en) 2022-04-13
US10294289B2 (en) 2019-05-21
US11021528B2 (en) 2021-06-01
PL3481859T3 (pl) 2022-07-11
IL264030A (en) 2019-01-31
JP2022096660A (ja) 2022-06-29

Similar Documents

Publication Publication Date Title
ZA201900507B (en) Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof
IL273327A (en) Chimeric polypeptides and their uses
IL281273A (en) Adapted 21–FGF polypeptides and their uses
IL275463A (en) TLR7/8 antagonists and their use
SG11202006420TA (en) Transferrin receptor-binding polypeptides and uses thereof
IL273253A (en) Glucagon-like peptide-1 receptor agonists and their uses
IL292692B1 (en) Mrgprx2 antagonists and their uses
IL280808A (en) OX40-binding polypeptides and their uses
IL272749A (en) Soluble interferon receptors and their uses
PL3405222T3 (pl) Nowe polipeptydy i ich zastosowania medyczne
GB2603645B (en) Polypeptides having anti-senescent effects and uses thereof
IL287782A (en) 33cd-binding polypeptides and their uses
SG11201912799SA (en) Recombinant human-basic fibroblast growth factor (rh-bfgf) and pharmaceutical composition comprising rh-bfgf
IL274751A (en) ILDR2 antagonists and combinations thereof
GB201819200D0 (en) Polypeptide and uses thereof
GB201707139D0 (en) Polypeptides
GB201812328D0 (en) Polypeptides and uses thereof
GB201712266D0 (en) polypeptides and uses thereof
GB201712268D0 (en) Polypeptides and uses thereof
HK40031554A (en) Soluble interferon receptors and uses thereof
HK40023936A (en) Glucagon-like peptide 1 receptor agonists and uses thereof
HK40050222A (en) Ox40-binding polypeptides and uses thereof
AU2017901183A0 (en) Polypeptides and uses thereof
AU2018904117A0 (en) Polypeptides and uses thereof
GB201801920D0 (en) Polypeptides and methods